Navigation Links
Metabolex Initiates Phase 1 Trial of MBX-2982
Date:3/26/2008

- Potential First-in-Class Treatment for Type 2 Diabetes -

HAYWARD, Calif., March 26 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has dosed the first cohort of healthy subjects in a Phase 1 clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes.

The Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBX-2982. Investigators expect to enroll a total of 60 healthy volunteers in the 6-cohort ascending-dose study.

MBX-2982 is an agonist of GPR119, a G-protein coupled receptor (GPCR) that is expressed in pancreatic islets and the gastrointestinal tract. Pre-clinical studies conducted by Metabolex and others show that GPR119 agonists can stimulate glucose-dependent insulin secretion and may preserve beta cell health -- properties that mimic incretins such as GLP-1, and exenatide (a GLP-1 analogue marketed as Byetta(R)). Unlike exenatide, however, MBX-2982 can be delivered orally. In addition, MBX-2982 may provide additional benefit when used in combination with a DPP-4 inhibitor such as sitagliptin (Januvia(R)), or other oral therapies.

"We have identified a number of potent GPR119 agonists that improve glucose control in normal and diabetic animal models," said David B. Karpf, MD, chief medical officer of Metabolex. "Advancing MBX-2982 into Phase 1 represents a significant achievement in the expansion of our clinical pipeline and further validates our research and development capabilities."

About Diabetes

Diabetes is a worldwide health problem and a rapidly growing source of illness, death and health care costs. According to the International Diabetes Federation, approximately 230 million people, or almost 6 percent of the world's population, had diabetes in 2006. The American Diabetes Association estimates that there were approximately 20.8 million people in the United States with diabetes in 2005, making up 9.6 percent of the adult population. From 1995 through 2005, newly-diagnosed cases of diabetes among American adults increased by 81 percent. According to estimates from the ADA, approximately 11 percent of U.S. healthcare dollars are spent on treating diabetes. Type 2 diabetes accounts for roughly 90 to 95 percent of diabetic cases.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has just commenced a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) ... th Annual Healthcare Conference on Monday, March 6, ... MA. A live webcast of Infinity,s presentation ... website at www.infi.com , and will be available ... Infinity,Infinity is an innovative biopharmaceutical company dedicated to advancing ...
(Date:2/27/2017)... Inc. (NASDAQ: IPXL ) today announced that it plans to ... Raymond James and Associates, 38 th Annual Institutional Investors Conference ... FL. Cowen and Company 37 th ... in Boston, MA. Barclays Global ... Miami, FL. Individuals may listen to ...
(Date:2/27/2017)... -- A recent research report published by Grand View ... expected to reach a value of $55.8 billion by 2025. Earlier ... states have legalized marijuana for medical uses. In 2016, states such ... North Dakota , Ohio ... drug in medical applications such as chemotherapies and pain management. The ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from ... scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society ... B. Liegner, M.D. has compiled into a single volume a compelling argument that the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre ... Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of ... showcases the Centre's commitment to innovation in drug rehab and alcohol treatment strategies ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... and environs, is proud to announce an upgrade to the company's Yelp listing. ... Yelp page on topics as diverse as Platelet Rich Plasma (PRP) therapy, hair ...
(Date:2/26/2017)... , ... February 25, 2017 , ... The February 13, ... heightened awareness and concern over nerve agents and the deadly use of chemical weapons. ... nervous system and how even small doses can be lethal. , Jay Jagannathan, M.D., ...
Breaking Medicine News(10 mins):